Table 2.
Summary of published data for routine inflammatory biomarkers.
| Reference | Tumor | No. of patients | Study | Marker | Outcomes | Significance |
|---|---|---|---|---|---|---|
| Eun Young Kim et al.19 | SCLC | 186 | Retrospective | ALI | Low ALI Good prognosis |
Univariate
HR 2.10 95% CI 1.50 ± 2.94 p value <0.001 Multivariate HR 1.67 95% CI 1.17 ± 2.37 p value 0.004 |
| Masayuki Okui et al.7 | LCNEC | 1890 | Retrospective | NLR | High NLR Poor prognosis |
Multivariate
HR 8.559 95% CI 1.260–58.139 p value 0.028 |
| Laura Mezquita et al.8 | NSCLC | 466 | Retrospective | LIPI | High LIPI Poor prognosis |
3 months [95% CI, 1 month to not reached (NR)] versus 10 months (95% CI, 8 months to NR) versus 34 months (95% CI, 17 months to NR) for the poor, intermediate, and good LIPI groups, respectively (p < 0.001) |
| Xiuxiu Zhang et al.6 | SCLC | 4785 | Meta-analysis | LDH | High LDH Poor prognosis |
HR 1.45 95% CI 1.27–1.66 |
| Xuan Hong et al.21 | SCLC | 919 | Retrospective | NLR | High NLR Poor prognosis |
HR 0.908 95% CI 0.721–1.144 p value 0.413 |
| Min Deng et al.22 | SCLC | 320 | Retrospective | NLR, LDH | High NLR Poor prognosis High LDH Poor prognosis |
NLR
HR 1.35 95% CI 1.02–1.79 p value 0.039 LDH HR 1.46 95% CI 1.10–1.96 p value 0.010 |
| Dan Liu et al.24 | SCLC | 139 | Retrospective | NLR | High NLR Poor prognosis |
Univariate analysis
NLR >4.55 versus ⩽4.55 HR 3.309 95% CI 2.088–5.244 p value 0.000 Multivariate analysis HR 2.093 95% CI 1.079–4.063 p value 0.029 |
| Xin Wang et al.23 | SCLC | 153 | Retrospective | NLR | High NLR Poor prognosis |
HR 1.724 95% CI 1.116–2.663 p value 0.014 |
ALI, advanced lung cancer inflammation index; CI, confidence interval; HR, hazard ratio; LCNEC, large cell neuroendocrine carcinoma; LDH, lactate dehydrogenase; LIPI, lung inflammation prognostic index; NLR, neutrophil-to-lymphocyte ratio; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.